We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
A hexokinase isoenzyme switch in human liver cancer cells promotes lipogenesis and enhances innate immunity.
- Authors
Perrin-Cocon, Laure; Vidalain, Pierre-Olivier; Jacquemin, Clémence; Aublin-Gex, Anne; Olmstead, Keedrian; Panthu, Baptiste; Rautureau, Gilles Jeans Philippe; André, Patrice; Nyczka, Piotr; Hütt, Marc-Thorsten; Amoedo, Nivea; Rossignol, Rodrigue; Filipp, Fabian Volker; Lotteau, Vincent; Diaz, Olivier
- Abstract
During the cancerous transformation of normal hepatocytes into hepatocellular carcinoma (HCC), the enzyme catalyzing the first rate-limiting step of glycolysis, namely the glucokinase (GCK), is replaced by the higher affinity isoenzyme, hexokinase 2 (HK2). Here, we show that in HCC tumors the highest expression level of HK2 is inversely correlated to GCK expression, and is associated to poor prognosis for patient survival. To further explore functional consequences of the GCK-to-HK2 isoenzyme switch occurring during carcinogenesis, HK2 was knocked-out in the HCC cell line Huh7 and replaced by GCK, to generate the Huh7-GCK+/HK2− cell line. HK2 knockdown and GCK expression rewired central carbon metabolism, stimulated mitochondrial respiration and restored essential metabolic functions of normal hepatocytes such as lipogenesis, VLDL secretion, glycogen storage. It also reactivated innate immune responses and sensitivity to natural killer cells, showing that consequences of the HK switch extend beyond metabolic reprogramming. Many cancers fuel their rapid growth by replacing glucokinase with its higher affinity isoenzyme, hexokinase 2 (HK2), making HK2 an attractive drug target. In this study, Perrin-Cocon and Vidalain et al. use CRISPR/Cas-9 gene editing to reverse this enzymatic switch in human liver cancer cells, and find this restores innate immune function as well as reversing cancer-associated metabolic reprogramming.
- Subjects
GLUCOKINASE; ISOENZYMES; CANCER cells; LIPID synthesis; NATURAL immunity; HEPATOCELLULAR carcinoma
- Publication
Communications Biology, 2021, Vol 4, Issue 1, p1
- ISSN
2399-3642
- Publication type
Article
- DOI
10.1038/s42003-021-01749-3